Latham, New York | May 28, 2026
AngioDynamics announced that Palmetto GBA has issued a final Local Coverage Determination (LCD L40205) establishing Medicare coverage guidance for the company’s NanoKnife® System in two important clinical indications: favorable intermediate-risk prostate cancer and metastatic colorectal cancer to the liver. The coverage determination becomes effective on July 5, 2026, creating a significant reimbursement pathway for patients eligible for treatment with irreversible electroporation (IRE), a non-thermal tissue ablation technology. The decision follows the activation of Category I CPT codes for prostate and liver IRE procedures earlier this year, further strengthening reimbursement support and physician access to the technology.
Medicare Coverage Framework Strengthens NanoKnife Adoption
The final Medicare coverage policy provides reimbursement guidance for appropriately selected prostate cancer patients and for metastatic colorectal cancer patients whose liver tumors cannot be safely removed surgically or treated with conventional thermal ablation. According to AngioDynamics, the combination of Category I CPT codes and Palmetto GBA coverage establishes an important infrastructure supporting broader payer adoption across the United States. Company executives noted that the decision represents a major step toward expanding patient access while helping physicians incorporate NanoKnife IRE into routine clinical practice for complex cancer cases.
NanoKnife Offers Non-Thermal Treatment for Complex Tumors
Unlike conventional thermal ablation technologies that rely on heat, NanoKnife IRE uses high-voltage electrical pulses to create permanent openings in cell membranes, triggering targeted cell death while preserving critical surrounding structures such as nerves, blood vessels, bile ducts, and the urethra. This unique mechanism makes the technology particularly valuable for treating tumors located near sensitive anatomical structures where thermal approaches may pose higher risks. The system is FDA-cleared for surgical ablation of soft tissue, including prostate tissue, and continues to gain attention as a minimally invasive option for challenging cancer cases.
Advertisement
Clinical Guidelines and Evidence Support Expanded Access
The Medicare determination aligns with guidance from major medical organizations, including the American Urological Association (AUA), the American Society for Radiation Oncology (ASTRO), and the National Comprehensive Cancer Network (NCCN). The final LCD incorporates clinical evidence submitted by AngioDynamics, physicians, and investigators during the public comment process, including updated patient selection criteria and references to published research supporting IRE use. Company leadership believes the reimbursement milestone will accelerate adoption of NanoKnife technology while supporting broader national coverage discussions and improving treatment access for patients facing prostate and liver cancers..
Source: AngioDynamics press release
